1. Home
  2. HRMY vs LCID Comparison

HRMY vs LCID Comparison

Compare HRMY & LCID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$35.34

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Lucid Group Inc.

LCID

Lucid Group Inc.

HOLD

Current Price

$6.30

Market Cap

2.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
LCID
Founded
2017
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
HRMY
LCID
Price
$35.34
$6.30
Analyst Decision
Buy
Hold
Analyst Count
9
7
Target Price
$44.11
$15.71
AVG Volume (30 Days)
910.7K
25.5M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
N/A
EPS
0.55
N/A
Revenue
$868,453,000.00
$595,271,000.00
Revenue This Year
$19.75
$71.67
Revenue Next Year
$12.88
$89.72
P/E Ratio
$65.09
N/A
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$1.97
52 Week High
$40.87
$25.22

Technical Indicators

Market Signals
Indicator
HRMY
LCID
Relative Strength Index (RSI) 51.31 50.83
Support Level $35.05 $5.59
Resistance Level $35.47 $6.85
Average True Range (ATR) 1.59 0.90
MACD -0.20 0.06
Stochastic Oscillator 46.08 72.09

Price Performance

Historical Comparison
HRMY
LCID

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About LCID Lucid Group Inc.

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design, which led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.

Share on Social Networks: